These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26787389)

  • 1. Urinary incontinence: Shock waves enable BoNT-A uptake by urothelium.
    Sidaway P
    Nat Rev Urol; 2016 Mar; 13(3):122. PubMed ID: 26787389
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Kilinc M; Guven S
    Eur Urol; 2010 May; 57(5):895-6. PubMed ID: 19394134
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Giannantoni A
    Eur Urol; 2010 May; 57(5):896. PubMed ID: 19394135
    [No Abstract]   [Full Text] [Related]  

  • 4. Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
    Liu HT; Chen SH; Chancellor MB; Kuo HC
    PLoS One; 2015; 10(8):e0134803. PubMed ID: 26241848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Khan S; Panicker J; Roosen A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ; Kessler TM
    Eur Urol; 2010 May; 57(5):891-6. PubMed ID: 19394133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children.
    Blackburn SC; Jones C; Bedoya S; Steinbrecher HA; Malone PS; Griffin SJ
    J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical electromotive botulinum toxin type A administration: part I--Experimental study.
    Kajbafzadeh AM; Montaser-Kouhsari L; Ahmadi H; Sotoudeh M
    Urology; 2011 Jun; 77(6):1460-4. PubMed ID: 21168901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia.
    Kuo HC
    Int J Clin Pract; 2013 Oct; 67(10):1044-9. PubMed ID: 24073977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary incontinence: what's new in therapy?].
    Becher KF; Sieber CC
    Dtsch Med Wochenschr; 2015 Feb; 140(3):164-7. PubMed ID: 25658400
    [No Abstract]   [Full Text] [Related]  

  • 11. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results.
    Kessler TM; Khan S; Panicker JN; Elneil S; Brandner S; Fowler CJ; Roosen A
    Eur Urol; 2010 May; 57(5):879-83. PubMed ID: 19765885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity.
    Ha US; Park EY; Kim JC
    Urology; 2011 Sep; 78(3):721.e1-721.e6. PubMed ID: 21782224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.
    Bagi P; Biering-Sørensen F
    Scand J Urol Nephrol; 2004; 38(6):495-8. PubMed ID: 15841785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children.
    Greer T; Abbott J; Breytenbach W; McGuane D; Barker A; Khosa J; Samnakay N
    J Pediatr Urol; 2016 Apr; 12(2):94.e1-6. PubMed ID: 26472538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.
    Janicki JJ; Chancellor MB; Kaufman J; Gruber MA; Chancellor DD
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
    Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury.
    Munoz A; Somogyi GT; Boone TB; Smith CP
    Neurourol Urodyn; 2011 Sep; 30(7):1376-81. PubMed ID: 21509809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.
    Kanai A; Wyndaele JJ; Andersson KE; Fry C; Ikeda Y; Zabbarova I; De Wachter S
    Neurourol Urodyn; 2011 Jun; 30(5):684-91. PubMed ID: 21661014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urethral and bladder injections for incontinence including botox.
    Appell RA
    Urol Clin North Am; 2011 Feb; 38(1):1-6, v. PubMed ID: 21353073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recalcitrant overactive bladder patient.
    Ghoniem GM
    Geriatrics; 2002 May; 57 Suppl 1():23-9. PubMed ID: 12040600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.